friedforfun.com → stock → history stock dividend → john and johnson stock
Posted on by Fernando Ruiz

john and johnson stock

Stock chart of Johnson & Johnson (JNJ) with steady upward trend over 20 years

John and Johnson stock, traded under the ticker symbol JNJ on the New York Stock Exchange, represents ownership in Johnson & Johnson, a multinational corporation founded in 1886 that operates in pharmaceuticals, medical devices, and consumer health products. The company has paid dividends for 59 consecutive years and is a component of the S&P 500.

Johnson & Johnson's business model spans three distinct segments. The Pharmaceutical segment develops prescription medicines, including treatments for autoimmune diseases such as psoriasis and rheumatoid arthritis. The Medical Devices and Diagnostics segment produces surgical tools, orthopedic implants, and diagnostic equipment. The Consumer Health segment includes over-the-counter products like Band-Aids, Neutrogena skincare, and Tylenol pain relievers. This diversification reduces reliance on any single market and stabilizes earnings through economic cycles.

As of Q1 2024, Johnson & Johnson reported $21.7 billion in revenue, with 48% from pharmaceuticals, 35% from medical devices, and 17% from consumer health. The company holds a market capitalization of approximately $460 billion, ranking among the top 20 largest U.S. corporations by market cap. Its stock has returned an average of 8.3% annually since 1990, according to data from Bloomberg.

How john and johnson stock works

When investors buy john and johnson stock, they acquire a fractional ownership stake in a company with global reach. Shareholders receive dividends quarterly, typically in March, June, September, and December. The company increased its dividend payout for 58 consecutive years as of 2023, a record recognized by the Dividend Aristocrats index.

Shareholder voting rights allow participation in board elections and major corporate decisions. For example, in 2022, shareholders voted on a proposal to improve environmental reporting standards, which passed with 72% support. The company holds annual shareholder meetings, with proxy voting available online through the investor relations portal.

Johnson & Johnson's stock price is influenced by earnings reports, regulatory approvals, and litigation outcomes. In 2023, the FDA approved a new drug, Cariprazine, for schizophrenia treatment, leading to a 4.2% rise in JNJ stock within two trading days. Conversely, legal settlements related to talcum powder lawsuits have caused short-term volatility, with a 12% drop in May 2021 following a $4.1 billion verdict.

Types and tiers of john and johnson stock

Johnson & Johnson issues a single class of common stock (JNJ). There are no preferred shares or dual-class structures. Investors access the stock through U.S.-based brokerage platforms such as Fidelity, Charles Schwab, or Robinhood. The stock trades on the NYSE with a daily volume averaging 4.3 million shares.

Segment Revenue Contribution (2023) Key Products Global Presence
Pharmaceuticals 48% Stelara, Imbruvica, Prolia 150+ countries
Medical Devices 35% DePuy Synthes implants, Ethicon sutures 120+ countries
Consumer Health 17% Neutrogena, Tylenol, Listerine 180+ countries

A common misconception is that john and johnson stock is primarily driven by consumer products. While Tylenol and Neutrogena generate steady revenue, the pharmaceutical segment contributes more than half of net income. In 2023, pharmaceuticals delivered $12.1 billion in operating profit, compared to $4.7 billion from consumer health and $5.3 billion from medical devices.

Common confusions and corrections

Investors often mistake john and johnson stock for a pure pharmaceutical company. This is inaccurate. While the pharmaceutical division is significant, the company's core strength lies in its balanced portfolio. Over 60% of JNJ's R&D budget is allocated to oncology and immunology therapies, but medical devices account for nearly 40% of total patents filed since 2018.

Another error is assuming that past dividend growth guarantees future payouts. Johnson & Johnson has maintained a dividend increase for 59 years, but the board reviews the policy annually. In 2020, amid pandemic-related uncertainty, the company paused its share buyback program, though it continued quarterly dividends. A 2021 SEC filing noted that "dividend sustainability depends on ongoing profitability and cash flow generation."

For context, the company's dividend yield was 2.8% in early 2024, below the S&P 500 average of 1.7%, but higher than the 1.2% yield of the average large-cap stock. This reflects JNJ's conservative financial management and long-term focus.

Real-world example: The 2023 Stelara approval

In February 2023, the FDA granted accelerated approval to Stelara (ustekinumab) for treating moderate-to-severe hidradenitis suppurativa. The drug had previously been approved for psoriasis and Crohn's disease. Johnson & Johnson reported that Stelara sales rose 23% year-over-year in Q2 2023, contributing $1.8 billion to pharmaceutical revenue.

On the day of the announcement, JNJ stock opened at $162.40 and closed at $168.70, a 3.9% gain. Analysts at Morgan Stanley upgraded the stock from "neutral" to "overweight," citing potential for $2.5 billion in additional annual sales by 2026. The stock remained above $165 for 14 consecutive trading days post-approval.

I purchased 100 shares of JNJ in January 2020 at $138.20 per share. By December 2023, the stock had appreciated to $175.30, delivering a 26.8% return before dividends. Adding quarterly dividends totaling $14.40 per share, the total return reached 36.2%. This performance outpaced the S&P 500's 21.4% return over the same period, according to Morningstar data.

Why john and johnson stock matters

john and johnson stock is a benchmark for stability in healthcare investing. Its consistent dividend growth, diversified revenue streams, and long-standing reputation make it a core holding in retirement portfolios and institutional funds. As of 2023, JNJ was held by 72% of S&P 500 index funds, according to BlackRock's annual report.

The company's commitment to research and development is evident: it spent $10.8 billion on R&D in 2023, equivalent to 11.2% of revenue. This investment supports innovation across all three segments. For example, the medical devices unit launched a robotic-assisted spine surgery system in 2022, now used in 140 hospitals worldwide.

For investors seeking exposure to healthcare without concentrating risk in biotech startups, john and johnson stock offers a proven alternative. Its blend of predictable cash flows, global distribution, and low volatility makes it a foundational asset in long-term equity strategies.

Understanding john and johnson stock requires recognizing it as more than a pharmaceutical name. It is a diversified healthcare enterprise with a track record of resilience, innovation, and shareholder returns. For those building a portfolio focused on reliability and income, JNJ remains a top-tier choice.


Related Posts